Shares of Large-cap health care company Biogen moved 0.5 this evening, and are now trading at $262.26 per share. On the other hand, the average analyst target price for the stock is $332.76.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Biogen Investors Should Consider This:
-
Biogen has moved -1.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 34.12. A number between 0 and 1 could mean that the market is undervaluing Biogen's estimated growth potential
-
Its Price to Book (P/B) ratio is 2.62
Understanding Biogen's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-15 | 10,173,400 | -4,634,700 | 32 | -5.88 |
| 2022-02-03 | 10,981,700 | -5,175,500 | 34 | -10.53 |
| 2021-02-03 | 13,444,600 | -6,495,400 | 38 | -29.63 |
| 2020-02-06 | 14,377,900 | -4,655,300 | 54 | 17.39 |
| 2019-02-06 | 13,452,900 | -5,450,800 | 46 | 2.22 |
| 2018-02-01 | 12,273,900 | -5,114,500 | 45 |
Biogen's operating margins have averaged 41.5% over the last 6 years, which is significantly higher than the Pharmaceutical industry average of 12.02%. However the firm's margins are declining at a compounded yearly rate of -5.5%.
